Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
Sancho JM, Abrisqueta P, Kumar A, Cordoba R, Tani M, Langmuir P, Rappold E, Liu T, Lopez-Guillermo A. Sancho JM, et al. Among authors: rappold e. Leuk Lymphoma. 2024 Jul;65(7):911-921. doi: 10.1080/10428194.2024.2331626. Epub 2024 Apr 10. Leuk Lymphoma. 2024. PMID: 38598516 Free article. Clinical Trial.
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Phillips TJ, Avigdor A, Gurion R, Patti C, Corradini P, Tani M, Mehta A, Lossos IS, Zinzani PL, Thieblemont C, Jurczak W, Zheng F, Rappold E, Zhao W, Jiang P, Johnson P. Phillips TJ, et al. Among authors: rappold e. Blood Adv. 2024 Feb 27;8(4):867-877. doi: 10.1182/bloodadvances.2023010648. Blood Adv. 2024. PMID: 38113459 Free PMC article. Clinical Trial.
32 results